For its 2019 list, Fortune collected survey responses from more than 3,750 analysts, directors and executives who rated companies based on nine categories, including long-term investment value, innovation and social responsibility.
Pharmaceutical executives and non-pharmaceutical executives shared a positive view of J&J, helping the drugmaker claim the No. 17 spot on Fortune‘s “All-Star” list. It ranks among other big names such as Amazon, Apple, Starbucks and Netflix.
When assessing pharma companies, J&J finished first in each of the nine categories assessed. Seven other pharmaceutical companies made the list, including Merck, Roche, Novartis, Amgen, Bristol-Myers, Pfizer and AbbVie.
The placement on the Fortune list comes amid a string of negative news reports about J&J. In December, it was reported that the pharma company knew for decades that carcinogenic asbestos lurked in its baby powder.
This week, J&J paid $120 million to settle a lawsuit with 46 states, claiming that its DePuy unit used deceptive marketing techniques to sell its metal-on-metal hip implants.
More articles on pharmacy:
Bayer to shut down Pennsylvania plant, eliminate 600 jobs
New drug shortages rose 27% in 2018
FDA moves to fast-track OTC naloxone
